Here we note some of the latest developments and news in the field of EECP.
April 2012 - EECP Experience at Dove Clinic This external blog was put together by one of the Dove Clinic’s patient’s, Joe Hill and provides an insight to the treatment, how the patient tolerates the treatment and how progress was made along the treatment course. Read the most recent postings externally
June 20, 2012 (Westbury, New York) - Vasomedical - “Mayo Clinic Talks” About Options For The Unrevascularizable Patient - Starting out by noting that an estimated 15% of patients in the cath lab are unrevascularizable, Dr. Bernard Gersh and Dr. Amir Lerman of the Mayo Clinic discussed the therapeutic options for these patients, including Enhanced External Counterpulsation (EECP®) Therapy on the audio blog called Mayo Clinic Talks. Dr. Gersh and Dr. Lerman discussed their definition of optimal medical therapy in this patient set, other solutions that have failed and solutions that are currently being used with documented results. When asked by Dr. Gersh if he thought “the effects seen in patients treated with EECP® therapy were real or placebo,” Dr. Lerman responded, “EECP® is real, we see a good response.” Further commenting on the subject, Dr. Gersh noted that “the magnitude of benefit is so great, I can’t believe that it's placebo.” Read On and Listen
June 5, 2012, WESTBURY, N.Y. - Vasomedical - EECP® Therapy Discussed - Heart Disease is America’s most costly disease according to the American Heart Association, and informing patients of a proven treatment option that is available and reduces costs has been a long term conviction of Dr. Joseph J. Tartaglia, Assistant Professor of Medicine at New York Medical College and a board certified cardiologist in private practice. Dr. Tartaglia appeared as a guest on “Long Island Viewpoint” with host Ken Rosato on WABC-TV Channel 7 in New York City on Sunday, June 3, 2012 to discuss EECP® Therapy. Watch the interview
January 20, 2012 - Chapter Dedicated to EECP® Therapy in New Textbook on Coronary Artery Disease
Included in the textbook is a chapter by Dr. Bradley Bart, Chief of Cardiology at Hennepin County Medical Center in Minneapolis, MN on Enhanced External Counterpulsation (EECP®) Therapy. In his chapter on EECP® Therapy, Dr. Bart thoroughly covers the initial development, clinical applications and possible mechanisms of action of counterpulsation therapy as currently used in the treatment of ischemic heart disease. Dr. Bart is also the Director of Clinical Programs at Hennepin County Medical Center, including nuclear cardiology, EECP® Therapy(enhanced external counterpulsation for the treatment of severe angina), therapeutic hypothermia for the treatment of cardiac arrest survivors, and ultrafiltration for advanced heart failure. Read the full overview
January 20, 2012 - International EECP Therapists Association Announces “International EECP Therapy Week” in February - Pittsburgh, PA (PRWEB) - The International EECP® Therapists Association (“IETA”) (The Dove Clinic has joined!), announced today in recognition of February as American Heart Month, the IETA has declared the week of February 20th – 24th, 2012 as the first annual “International EECP® Therapy Week”. With approximately 600 EECP® therapy centers in the United States and more than 250 in countries across the globe, the IETA has invited all EECP® therapy facilities to demonstrate their dedication to their patients and the medical communities they serve by celebrating Heart Month in a way that will increase awareness in the public and the healthcare communities internationally about Enhanced External Counterpulsation (EECP®), an FDA cleared, Medicare covered, non-invasive outpatient therapy for the treatment of symptoms in angina and congestive heart failure. Read on externally
January 10, 2012 - Florida Patient with MicroVascular Angina Benefits from EECP® Therapy - Dr. Ken Kronhaus, of Lake Cardiology in Mount Dora, Florida has recently appeared on multiple local TV News stations in Florida discussing the benefits of EECP® therapy for angina patients, including those patients who suffer from a specific form of angina called microvascular angina, which is sometimes referred to as cardiac syndrome X. Microvascular angina or cardiac syndrome X results when the tiny arteries in the heart are affected by microvascular disease or damage. Read on/see the video externally
Jan. 5, 2012, Studies Show Beneficial Effect of Enhanced External Counterpulsation (EECP) Therapy in Diabetic Patients - University of Florida Findings Demonstrate Improved Peripheral Artery Function, Glucose Tolerance and Glycemic Control. Vasomedical, Inc. ("Vasomedical") , a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, today announced the third party publication of a seminal study on the positive effects of Enhanced External Counterpulsation (EECP(R)) therapy in patients with non-insulin dependent abnormal glucose tolerance (AGT), providing what is considered as "novel evidence that EECP has a beneficial effect on peripheral arterial function and glucose tolerance in subjects with AGT." Read on Externally
4 December 2011 - Rosedale Cardiologist Says Non-invasive EECP Therapy Allows Heart Patients to Get Out of the House and Be Active without Chest Pain, Shortness of Breath, or Fatigue - Dr. Ola Akinboboye of Laurelton Heart Specialists says studies suggest EECP treatments may also improve sexual function in coronary artery disease patients with erectile dysfunction. Dr. Ola Akinboboye, Medical Director of Laurelton Heart Specialists in Rosedale, New York, has announced his clinic is offering a non-invasive treatment for increasing blood flow to the heart called Enhanced External Counterpulsation (EECP) therapy. Read on externally
2 December 2011 - Vasomedical announced today that it had added a new feature to its EECP.com web site. This new feature, which will provide a list of interviews about EECP® therapy, along with links to available media clips, is being added as a result of seeing a significant increase in interest for EECP® therapy, reflected in the increasing number of TV and radio interviews about EECP® therapy in the past two weeks and the interviews requested in the coming weeks. Follow the link.
28 November 2011 - Ohio Clinic passes 1000 EECP Patients Treated- Dr Charles W. Abbottsmith has announced that his clinic, The Ohio Heart and Vascular Center, is offering a painless, non-invasive therapy called Enhanced External Counterpulsation (EECP®) for Cincinnati-area residents suffering from angina and congestive heart failure. A practicing cardiologist in the Cincinnati area since 1971, Dr. Abbottsmith says his clinic has, over the past thirteen years, successfully delivered EECP® treatments to more than one thousand heart disease patients to relieve chest pain, fatigue, shortness of breath, and other conditions associated with restricted coronary blood flow. “We routinely see reductions in angina symptoms and fatigue after ten to fifteen one-hour treatments,” says Dr. Abbottsmith. “We’ve had patients brought to us in wheelchairs for their first treatment, and in a short time they’re able to walk in and out of the clinic on their own and drive themselves to and from treatments.”
21 November 2011 - Positive Developments in Stroke Therapy Using FDA Approved EECP Treatments - Global Cardio Care Centers is the largest physician practice dedicated to delivery of EECP cardiovascular therapy. Physicians in the practice suggest EECP positively affects motor functions in stroke patients who undergo several courses of EECP treatment. The Sara Soulati Health For Life Program complements EECP treatment at the clinic. Read on for more on this development
16 November 2011 - At the American Heart Association Scientific Sessions in Orlando, Florida, Dr. Ozlem Soran, presented an abstract on EECP® therapy entitled: Long Term Clinical Outcomes and Major Adverse Cardiac Event Rates of Enhanced External Counterpulsation Therapy in the Real World Settings in Patients with Coronary Artery Disease and Left Ventricular Dysfunction. The presentation was part of the Prognosis in Stable Ischemic Heart Disease session. The aim of the study was to assess the long term clinical outcomes of EECP® therapy in patients with coronary artery disease and left ventricular disease (LVD) in the real world settings “without strict inclusion and exclusion criteria used in clinical trials.” Data from 1,276 patients was analyzed, 88% of the patients had multivessel disease with Canadian Cardiovascular Society III/IV functional class. Most patients reported their “quality of life” was poor. 79% of patients underwent treatment with EECP® therapy and completed 32 hours of therapy. 5% discontinued due to a clinical event, and 6% stopped due to patient preference. After completion of treatment, there was a significant decrease in severity of angina class, and 75% had angina reduction by at least one class; 47% discontinued nitroglycerin use and quality of life improved substantially. After two years, this decrease in angina was maintained in 74% of patients. The conclusion of the study is that EECP® therapy demonstrated an effective, long term treatment in the real world settings for angina pectoris management in patients with LVD and low major cardiovascular event rates.
Vitamin D for the heart - Giving vitamin D to patients after they’ve survived a heart attack or a close call lowers their levels of two compounds implicated in heart disease. Yoav Arnson of Meir Medical Center in Kfar Saba, Israel, and colleagues identified 50 patients - read more externally
Dr Debra Braverman talks on the bigger picture of heart disease prevention and how EECP can help. The WNLK discussion is well worth the listen. There are also a number of video and audio options by following this link.
John Hopkins Health Alert contains a useful overeview of Angina Basics - link to the external site
EECP Forum reports - Chapter on EECP® Therapy Included in a New Book on Angina - October 12, 2011
– Vasomedical is pleased to announce the inclusion of a chapter on its proprietary Enhanced External Counterpulsation (“EECP®”) therapy in today’s online publication of the book Angina Pectoris.... Read more on the Forum
October 2011 - Health Tip: Suggestions to Help Manage Angina
Angina describes the pain and discomfort that occurs when the heart lacks a sufficient supply of oxygenated blood. Read more on the MedicineNet.com site
5 September 2011 - CANOE Publishes New Angina factsheet
In this factsheet: - The Facts on Angina - Causes of Angina - Symptoms and Complications of Angina -
Diagnosing Angina - Treating and Preventing Angina Read More
12 August 2011 - Dove Publishes new testimonials
For many years I have had health problems, but in the last few years have suffered mainly with angina; unable to walk more than 50 yards and my chest would tighten so severely I was afraid to go out alone. Normal everyday things like my housework was so hard and took so long, having to rest a while so often, it was frustrating and depression set in. My life was so low mentally. Read More
9 August 2011- Hearty news: Surgery not needed for heart patience
A year ago, even a 10-metre walk left a 68-year-old Ramachandran gasping for breath. Even after he was diagnosed for cardiac blockage, he refused to opt for bypass surgery. Despite that, Ramachandran today. Read More
5 July 2011 - Vasomedical To Participate in the European Society of Cardiology (ESC) Congress in Paris, France on August 27-30, 2011.
Vasomedical will feature its full line of products at the ESC, including the company’s unique core technology, Enhanced External Counterpulsation (EECP®) therapy. The company will conduct live demonstrations of its therapy systems on its 4th generation model, the Lumenair™ EECP® therapy system. Read more
29 June 2011 - The Truth about EECP® and ECP Therapy
EECP® is a registered trademark for the external counterpulsation therapy (ECP) and equipment of Vasomedical Inc., Westbury, NY. Only Vasomedical may use the trademarked name for its proprietary Enhanced External Counterpulsation therapy. EECP® is more than just a trademark. Read more
Latest EECP News